Your browser doesn't support javascript.
loading
Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients.
Heudel, Pierre; Favier, Bertrand; Solodky, Marie-Laure; Assaad, Souad; Chaumard, Natacha; Tredan, Olivier; Bachelot, Thomas; Ray-Coquard, Isabelle; Russias, Bruno; Fournier, Marie-Line; Mastroianni, Benedicte; Avrillon, Virginie; Michallet, Anne-Sophie; Zrounba, Philippe; Chabaud, Sylvie; Perol, David; Blay, Jean-Yves.
Afiliação
  • Heudel P; Department of Medical Oncology, Centre Léon Bérard Cancer Center, Lyon, France.
  • Favier B; Department of Pharmacy, Centre Léon Bérard Cancer Center, Lyon, France.
  • Solodky ML; Department of Medecine of Health Care Workers, Centre Léon Bérard Cancer Center, Lyon, France.
  • Assaad S; Department of Medical Oncology, Centre Léon Bérard Cancer Center, Lyon, France.
  • Chaumard N; Department of Pharmacy, Centre Léon Bérard Cancer Center, Lyon, France.
  • Tredan O; Department of Medical Oncology, Centre Léon Bérard Cancer Center, Lyon, France.
  • Bachelot T; Department of Medical Oncology, Centre Léon Bérard Cancer Center, Lyon, France.
  • Ray-Coquard I; Department of Medical Oncology, Centre Léon Bérard Cancer Center, Lyon, France.
  • Russias B; Department DCSEI, Centre Léon Bérard Cancer Center, Lyon, France.
  • Fournier ML; Department DCSEI, Centre Léon Bérard Cancer Center, Lyon, France.
  • Mastroianni B; Department of Surgery, Centre Léon Bérard Cancer Center, Lyon, France.
  • Avrillon V; Department of Medical Oncology, Centre Léon Bérard Cancer Center, Lyon, France.
  • Michallet AS; Department of Medical Oncology, Centre Léon Bérard Cancer Center, Lyon, France.
  • Zrounba P; Department of Surgery, Centre Léon Bérard Cancer Center, Lyon, France.
  • Chabaud S; Department of Clinical Research, Centre Léon Bérard Cancer Center, Lyon, France.
  • Perol D; Department of Clinical Research, Centre Léon Bérard Cancer Center, Lyon, France.
  • Blay JY; Department of Medical Oncology, Centre Léon Bérard Cancer Center, Lyon, France; Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, France; Presidence, Unicancer, Paris, France. Electronic address: jean-yves.blay@lyon.unicancer.fr.
Eur J Cancer ; 165: 174-183, 2022 04.
Article em En | MEDLINE | ID: mdl-35245864
ABSTRACT

BACKGROUND:

Patients with cancer are at high risk of severe or lethal COVID-19. The impact of SARS-COV-2 vaccination on the risk of developing COVID-19 was investigated in an exhaustive series of patients from a comprehensive cancer center.

METHODS:

This is a study of the exhaustive population of 2391 cancer patients who were prescribed SARS-COV-2 vaccination until 09/21. Patient characteristics, documented SARS-COV-2 infection with RT-PCR, and survival were collected. The primary endpoint was the rate of COVID-19 after vaccination. Secondary endpoints included risk factors to develop COVID-19 after vaccination, with a comparison with the cohort of vaccinated health care workers (HCW), and risk factors for death.

RESULTS:

From January to September 2021, among 2391 patients with cancer under active treatment in whom a SARS-COV-2 vaccine was prescribed, 659 (28%), 1498 (63%) and 139 (6%) received 1, 2, and 3 doses, respectively. Ninety five patients received a single dose of vaccine after a previous COVID-19. Two thousand two hundred eighty five health care workers (HCW) received one (N = 17, 0.7%), 2-3 (N = 2026, 88.7%) vaccine doses and one dose after COVID-19 (N = 242, 10.6%). With a median follow-up of 142 and 199 days for patients and HCW, respectively. Thirty nine (1.6%) patients and 35 (1.5%) HCW developed COVID-19 after vaccination. Six of 39 cancer patients and no HCW died because ofCOVID-19 within 50 days after diagnosis. Independent risk factors for COVID-19 in vaccinated patients were age, single dose of vaccine without previous COVID-19 and anti-CD20 treatment in the last three months. Independent risk factors for death included metastatic disease, gender, cancer type, but also documented COVID-19 before vaccination.

CONCLUSIONS:

Patients receiving two or more doses of COVID-19 vaccine have reduced risk of COVID-19. The risk of death of vaccinated cancer patients presenting COVID-19 remains high. COVID-19 before vaccination is associated with an increased overall risk of death.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans / Infant Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans / Infant Idioma: En Ano de publicação: 2022 Tipo de documento: Article